Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BPRDP 056

Next Previous
Drug Profile

BPRDP 056

Alternative Names: BPRDP-056; T-1201

Latest Information Update: 28 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Molecular Targeting Technologies; National Health Research Institutes
  • Developer Taivex Therapeutics
  • Class Amines; Antineoplastics; Camptothecins; Drug conjugates; Indolizines; Pyrans; Quinolines; Small molecules; Zinc compounds
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Taiwan (IV, Infusion)
  • 27 Feb 2024 National Health Research Institutes and Molecular Targeting Technologies files for patent protection with WIPO for BPRDP 056 in multiple countries worldwide prior to February 2024 (Taivex Therapeutics pipeline, February 2024).
  • 27 Feb 2024 National Health Research Institutes and Molecular Targeting Technologies has patent protection for BPRDP 056 in USA, Taiwan, Japan, Australia, South Korea, New Zealand, India, European Union and other undisclosed countries prior to February 2024 (Taivex Therapeutics pipeline, February 2024).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top